Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
Κύριοι συγγραφείς: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Elsevier
2024
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
ανά: Jonathan Maurer, κ.ά.
Έκδοση: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
ανά: Alexander Meisel
Έκδοση: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
ανά: Nicolas Bourdillon, κ.ά.
Έκδοση: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
ανά: Church, D, κ.ά.
Έκδοση: (2012) -
REBOA: is it ready for prime time?
ανά: Jay Doucet, κ.ά.